Platinum Investment Management Ltd. purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 19,138 shares of the biopharmaceutical company’s stock, valued at approximately $1,598,000. Several other hedge funds have also made changes to their positions in the company. Seven Eight Capital LP purchased […]
Sectoral Asset Management Inc. reduced its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 94.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 7,013 shares of the biopharmaceutical company’s stock after selling 111,290 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Cytokinetics were worth $586,000 as of its most […]
Rhenman & Partners Asset Management AB lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,912 shares of the biopharmaceutical company’s stock after selling 50,088 shares during the quarter. Rhenman & Partners Asset […]
Rafferty Asset Management LLC lifted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 6.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 263,275 shares of the biopharmaceutical company’s stock after purchasing an additional 16,353 shares during the quarter. Rafferty Asset Management LLC’s […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective trimmed by JMP Securities from $106.00 to $78.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a market outperform rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the company. […]